$AQST News

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

Aquestive Therapeutics Files Prospectus For Offering 230,271 Common Shares On Behalf Of Selling Shareholders

Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?

Does US manufacturing give drugmakers a speed edge?

Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval

The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...

Aquestive Therapeutics Q1 Earnings Call Highlights

Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript

Aquestive Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript

Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics

Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $48.072M Est

Aquestive Therapeutics Q1 EPS $(0.07) Beats $(0.15) Estimate, Sales $14.446M Beat $10.896M Estimate

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Aquestive Therapeutics (AQST) Awaits Anaphylm NDA Approval in Q3

Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film